Dana-Farber Cancer Institute and Astellas Pharma Inc. announce three-year collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DANA-FARBER CANCER INSTITUTE and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login